


Best practices of nucleic acid amplification tests for the diagnosis of clostridioides (clostridium)

June 4 2019



This photograph depicts Clostridium difficile colonies after 48hrs growth on a blood agar plate; Magnified 4.8X. C. difficile, an anaerobic gram-positive rod, is the most frequently identified cause of antibiotic-associated diarrhea (AAD). It accounts for approximately 15–25% of all episodes of AAD. Credit: CDC

A new review looks at the challenges of testing for *Clostridioides* (Clostridium) *difficile* infection (CDI) and recommendations for newer diagnostic tests. Accurate diagnosis of CDI is critical for effective



patient management and implementation of infection control measures to prevent transmission. The research is published this week in the *Clinical Microbiology Reviews*.

CDI is the leading cause of healthcare-associated infections in the United States. It accounts for 15% to 25% of healthcare-associated diarrhea in all healthcare settings with a documented 453,000 cases of CDI and 29,000 deaths in the United States in 2015.

"This study emphasizes the issues related to the diagnosis of *C. difficile* infection, with the focus on newer nucleic amplification tests (NAAT)," said Colleen Kraft, MD, MSc, Emory University School of Medicine, who is the lead author on the study.

Since there is limited high-quality evidence to support which diagnostic testing strategy is best for the lab diagnosis of CDI, testing is difficult. There is currently no "gold" standard <u>test</u> to diagnose CDI. According to the report, among patients presenting with diarrhea there is significant potential for under-diagnosis. Over-diagnosis can also arise from incorrect diagnostic workups.

The review set out to address how effective NAAT testing practices were for diagnosing patients suspected of CDI. They evaluated NAAT tests alone, which detects the toxin gene, as well as algorithmic testing (NAAT plus GDH or toxin EIA). GDH Enzyme Immunoassay (EIA) testing detects the enzyme active in the organism, so effectively the organism, and toxin EIA detects the toxin protein. The researchers evaluated over 11,000 records found in electronic databases. 72 studies had sufficient data for meta-analysis.

The team concluded that the nucleic-acid amplification tests (NAAT) is the recommended practice for detecting the toxin gene. GDH/NAAT algorithm is recommended for detecting *C. difficile* organism/toxin



gene. The overall strengths of evidence for these practices were high and effects across studies were consistent. The GDH/TOXIN/NAAT algorithm is recommended for the *C. difficile* organism/toxin/toxin gene, although the overall strength of evidence for this practice was moderate. The researchers had no recommendation for repeat testing using NAAT-only testing within 7 days of a negative result.

Future research should look at whether clinical outcome reporting is necessary to determine which diagnostic test is most accurate. "We found in this <u>systematic review</u> that most of the studies we looked at did not have pre-analytic and clinical outcomes data. Our hope is that <u>future</u> <u>studies</u> will consider those aspects in order to determine the utility of these tests in patient diagnosis and patient care," said Dr. Kraft.

More information: Colleen S. Kraft et al, A Laboratory Medicine Best Practices Systematic Review and Meta-analysis of Nucleic Acid Amplification Tests (NAATs) and Algorithms Including NAATs for the Diagnosis of Clostridioides (Clostridium) difficile in Adults, *Clinical Microbiology Reviews* (2019). DOI: 10.1128/CMR.00032-18

Provided by American Society for Microbiology

Citation: Best practices of nucleic acid amplification tests for the diagnosis of clostridioides (clostridium) (2019, June 4) retrieved 18 July 2024 from <u>https://medicalxpress.com/news/2019-06-nucleic-acid-amplification-diagnosis-clostridioides.html</u>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.